ArticlePLoS medicine2025
Association between cigarette smoking status, intensity, and cessation duration with long-term incidence of nine cardiovascular and mortality outcomes: The Cross-Cohort Collaboration (CCC).
Article in PLoS medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between early menopause and adverse cardiovascular events in postmenopausal women: a systematic review and meta-analysis stratified by smoking status and type 2 diabetes mellitus.Frontiers in public health · 2026Pooled it
- ADHD and metabolic syndrome: behavioral and weight-related pathways to cardiovascular risk.European archives of psychiatry and clinical neuroscience · 2026Article
- Polyunsaturated fatty acids modulation of smoking-related epigenetics and pulmonary outcomes.Genes & nutrition · 2026Article
- Lifestyle Factors and Diet-Disease-Related Knowledge: A Network Psychometric Analysis of Cardiovascular Health Literacy Among Lebanese Adults.Nutrients · 2026Article
- A Narrative Review of the Potential Impact of Next-Generation Tobacco and Nicotine Products on Cardiovascular Health.Cureus · 2026Review
- Mental Distress and Smoking in Relation to Cardiovascular Mortality in the United States Population.Brain and behavior · 2026Article
- Meta-ERS: an exposome-based risk score using non-genetic factors to guide osteoporosis prevention.Journal of translational medicine · 2026Article
- Comprehensive Smoke-Free Laws and Cardiovascular Disease Mortality in US Counties.JAMA network open · 2026Article
- Tea intake as a dietary factor for cardiovascular health: global estimates of potentially preventable ischemic heart disease.Nutrition journal · 2026Article
- Workplace Sexual Harassment and the Risk of Chronic Disease in a Prospective Cohort Study.Behavioral sciences (Basel, Switzerland) · 2026Article
- Intergenerational and individual effects of smoking exposure on non-alcoholic fatty liver disease: A Mendelian randomization study.Tobacco induced diseases · 2026Article
- Association of active and passive smoking with noncommunicable diseases in a large health check-up population: A cross-sectional study in Changzhi, Shanxi province, China.Tobacco induced diseases · 2026Article
- Article
- Alarming Antimicrobial Prescribing Patterns at a Tertiary Hospital in Nigeria: A Point Prevalence Survey using the Global-PPS Protocol.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
backgroundUncertainties persist regarding the precise shape of the smoking-outcome curves across various cardiovascular and mortality endpoints. This study aims to elucidate the relationships among smoking burden, intensity, and cessation duration across multiple cardiovascular outcomes. METHODS AND
findingsCox proportional hazard models were constructed to evaluate the association between pack-years, cigarettes per day (CPD), and years since cessation with cardiovascular outcomes in participants from 22 prospective cohort studies within the Cross-Cohort Collaboration Tobacco Working Group. We evaluated myocardial infarction (MI), stroke, coronary heart disease (CHD; MI, coronary revascularization, or coronary death), cardiovascular disease (CVD; stroke or cardiovascular death), heart failure (HF), atrial fibrillation (AFib), CHD mortality, CVD mortality, and all-cause mortality. Median follow-up varied across outcomes, with 14.4 years for MI (17,570 events), 19.3 years for CHD (30,625 events), 18.6 years for CVD (54,078 events), and approximately 19.4-19.9 years for mortality outcomes (CHD mortality: 17,429 events; CVD mortality: 33,120 events; all-cause mortality: 125,044 events). Spline terms were used to investigate the nonlinear association of continuous smoking/cessation measures with the examined outcomes. Models were adjusted for demographic, socioeconomic, and other cardiovascular risk factors. The study included 323,826 adults (148,635 non-mortality and 176,396 mortality outcomes with 25 and 16 million person-years at risk, respectively). Compared to never-smokers, current smokers had significantly increased risks for CVD (hazard ratio (HR) 1.74, 95% confidence intervals (CIs) [1.66,1.83] in men; HR 2.07, 95% CI [2.00,2.14] in women) and all-cause mortality (HR 2.17, 95% CI [2.09,2.25] in men; HR 2.43, 95% CI [2.38,2.48] in women; all p < 0.001). Compared with never-smokers, participants with 2-5 CPD demonstrated substantially elevated cardiovascular risks, with HR ranging from 1.26 (95% CI [1.09,1.45], p = 0.002) for AFib to 1.57 (95% CI [1.39,1.78], p < 0.001) for HF. Smoking 2-5 CPD was associated with increased CVD mortality (HR 1.57, 95% CI [1.41,1.75]), and all-cause mortality (HR 1.60, 95% CI [1.52,1.69]; both p < 0.001). Smoking 11-15 CPD conferred a higher risk of CVD (HR 1.87, 95% CI [1.69,2.06]) and all-cause mortality (HR 2.30, 95% CI [2.14,2.47]; both p < 0.001). The increased risk associated with the evaluated outcomes was steeper for the initial 20 pack-years and 20 CPD, respectively, compared to further smoking exposure. The most substantial reduction in risk across all outcomes was observed within the first 10 years after smoking cessation. However, the progressive risk reduction continues over extended time periods, with former smokers demonstrating over 80% lower relative risk than those of current smokers within 20 years of cessation. Limitations include potential exposure misclassification due to reliance on single baseline self-reported smoking measurements with extended follow-up periods, which may underestimate true risk associations, and lack of data on other tobacco products and electronic nicotine delivery systems, preventing analysis of dual- and poly-use patterns.
conclusionLower-intensity smoking is associated with cardiovascular risk and the primary public health message for current smokers should be early cessation, rather than reducing the amount of smoking. Cessation provides substantial immediate risk reduction, although risk continues to decrease significantly for the following two decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.